A single agent trial of FLX 787 for treatment of cramps associated with amyotrophic lateral sclerosis (ALS)
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs FLX 787 (Primary)
- Indications Amyotrophic lateral sclerosis; Cramp
- Focus Therapeutic Use
- Sponsors Flex Pharma
- 02 Aug 2017 According to a Flex Pharma media release, the company expects important data readouts from this study in 2018.
- 25 Jul 2017 According to Flex Pharma media release, the company will end the exploratory Australian ALS study early, with roughly a dozen patients
- 13 Sep 2016 According to Flex Pharma media release, status changed from planning to recruiting.